PFIZER INC
For the period ended Jun 28, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 28, 2026 · Filed Aug 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Total Revenues by Geography
| The following presents worldwide Total revenues by geography: | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Three Months Ended | ||||||||||||||
| Worldwide · U.S. · International · World-wide · U.S. · Inter-national | ||||||||||||||
| (MILLIONS) · June 28,2026 · June 29,2025 · June 28,2026 · June 29,2025 · June 28,2026 · June 29,2025 · % Change | ||||||||||||||
| Operating segments: | ||||||||||||||
| Biopharma | $14,661 | $14,305 | $8,790 | $8,793 | $5,871 | $5,512 | 2 | — | 7 | |||||
| Pfizer CentreOne(a) | 373 | 348 | 67 | 101 | 306 | 247 | 7 | (34) | 24 | |||||
| Total revenues | $15,034 | $14,653 | $8,857 | $8,894 | $6,177 | $5,759 | 3 | — | 7 | |||||
| Six Months Ended | ||||||||||||||
| Worldwide · U.S. · International · World-wide · U.S. · Inter-national | ||||||||||||||
| (MILLIONS) | June 28,2026 | June 29,2025 | June 28,2026 | June 29,2025 | June 28,2026 | June 29,2025 | % Change | |||||||
| Operating segments: | ||||||||||||||
| Biopharma | $28,822 | $27,746 | $17,416 | $17,078 | $11,406 | $10,668 | 4 | 2 | 7 | |||||
| Pfizer CentreOne(a) | 662 | 622 | 172 | 190 | 490 | 432 | 7 | (10) | 14 | |||||
| Total revenues | $29,484 | $28,367 | $17,588 | $17,268 | $11,896 | $11,100 | 4 | 2 | 7 | |||||
(a)Includes revenues associated with the wind-down of our former Pfizer Ignite operating segment, which were not material in all periods presented. We reclassified prior period amounts to conform to the current period presentation.
Product Revenue Deductions––Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these product revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends.
| The following presents information about product revenue deductions: | ||||
|---|---|---|---|---|
| Three Months Ended | Six Months Ended | |||
| (MILLIONS) | June 28,2026 | June 29,2025 | June 28,2026 | June 29,2025 |
| Medicare rebates | $965 | $1,103 | $1,964 | $2,171 |
| Medicaid and related state program rebates | 434 | 390 | 792 | 787 |
| Performance-based contract rebates | 1,748 | 1,663 | 3,410 | 3,274 |
| Chargebacks | 3,581 | 3,204 | 6,782 | 6,143 |
| Sales allowances | 1,700 | 1,773 | 3,413 | 3,555 |
| Sales returns and cash discounts | 594 | 304 | 919 | 639 |
| Total | $9,022 | $8,436 | $17,280 | $16,569 |
Product revenue deductions are primarily a function of product sales volume, mix of products sold, contractual or legislative discounts and rebates.
For information on our accruals for product revenue deductions, including the balance sheet classification of these accruals, see Note 1B.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.